Recently, a new PRL-based mechanism by which PRL-treated breast cancer cell-secreted factors directly promote the differentiation of functional osteoclast cells capable of bone resorption was identified, which likely is responsible for the observed acceleration of clinical detection of bone metastasis in patients with high levels of the PRLR [1]. The gene discussed is PRL; the disease is breast carcinoma.